Radius raises $50.2M in follow-on

Radius Health Inc. (NASDAQ:RDUS) raised $50.2 million through the sale of 2.75 million shares at $18.25 in a follow-on underwritten by Jefferies; Cowen; and Cantor Fitzgerald. The company proposed the offering in a shelf registration after market close Oct. 1, when it finished the day at $19.14.

Radius' abaloparatide-SC is in Phase III testing to treat severe osteoporosis in postmenopausal women who are at risk of fracture. The candidate is a subcutaneous formulation of abaloparatide, a peptide analog of parathyroid hormone-related protein (PTHrP). Radius has ex-Japanese rights from Ipsen Group (Euronext:IPN; Pink:IPSEY). ...